BPC-157 (Body Protection Compound-157) is a synthetic peptide made of 15 amino acids. Its sequence is derived from a partial fragment of a protective protein found in human gastric juice, which is why much of the early research around it focused on the stomach and gut. It is usually sold as a lyophilized (freeze-dried) powder that is reconstituted with bacteriostatic water before use in research settings.

In plain English, the proposed mechanism goes like this: researchers believe BPC-157 may influence the growth of new blood vessels (angiogenesis), modulate nitric-oxide signaling, and interact with growth-factor pathways involved in tissue repair. In animal models these effects appear as faster healing of tendon, ligament, muscle, and gut tissue. It is important to be clear that these mechanisms have been characterized almost entirely in rodents and cell cultures — how, or whether, they translate to humans has not been established.

Regulatory status: BPC-157 is not approved by the FDA or any other major regulator for any medical use in humans. It has never completed the clinical-trial process that approved drugs go through. In 2023 the FDA placed BPC-157 in the category of bulk drug substances that raise significant safety risks when used in compounding, citing the lack of human safety data. Products sold online are typically labeled "for research use only," which is a legal framing, not a safety endorsement. BPC-157 is also prohibited in sport under the World Anti-Doping Agency's rules as a non-approved substance.

The BPC-157 evidence base is large in volume but narrow in kind: it consists overwhelmingly of preclinical work — rodent studies and in-vitro experiments — much of it from a small number of research groups. Published animal studies have examined:

• Tendon and ligament injury models (e.g., transected rat Achilles tendon), where treated animals showed faster functional recovery;
• Gastrointestinal damage models, including NSAID-induced gut lesions, fistulas, and inflammatory bowel injury in rodents;
• Muscle crush injuries, bone defects, and nerve injury models;
• Effects on blood-vessel formation and blood flow in injured tissue.

Human data, by contrast, is close to nonexistent. There are no published large randomized controlled trials of BPC-157 in humans, and no peer-reviewed human efficacy data for the injury-recovery uses it is most often discussed for. A small number of early-phase investigations have been referenced over the years, but none has produced published results that establish safety or efficacy in people.

It is also worth understanding why it is discussed so widely despite this. BPC-157 is inexpensive to synthesize, appears stable in gastric acid (which fed interest in oral use for gut conditions), and the rodent results in tendon and ligament models speak directly to injuries that heal slowly and frustrate athletes. That combination — plausible mechanism, relatable target, thin oversight — is precisely the profile of a compound whose popularity can outrun its evidence.

This gap matters. Many compounds that look promising in rodents fail in human trials — because of dosing differences, species differences in metabolism, or effects that simply do not replicate. An honest reading of the literature is: interesting preclinical signals, unproven in humans.

Because BPC-157 has not been through controlled human trials, its side-effect profile in people is essentially uncharacterized. That is itself the headline risk: unknown long-term safety. Anecdotal reports from self-experimenters (nausea, dizziness, fatigue, injection-site irritation) are unverified and cannot substitute for systematic safety data.

Specific concerns raised in the literature and by regulators include:

• Unknown long-term effects — no human data exists on chronic use, effects on tumor growth (a theoretical concern for any angiogenesis-modulating compound), fertility, or organ function;
• FDA compounding concerns — the FDA has flagged BPC-157 as a substance with significant safety risks and insufficient human safety information;
• Gray-market sourcing risk — "research use only" vendors are not held to pharmaceutical manufacturing standards. Independent testing of gray-market peptides has repeatedly found products with incorrect dosage, impurities, bacterial endotoxin contamination, or no active ingredient at all;
• Injection-related risks — any injected product prepared outside sterile pharmacy conditions carries infection risk;
• Anti-doping consequences — athletes subject to WADA rules can face sanctions for use.

Anyone considering any decision involving BPC-157 should discuss it with a licensed clinician first — including the fact that no human safety data exists.

There is no established human dose of BPC-157. That sentence deserves to stand alone: because no human dose-finding trials have been completed, nobody knows what an effective or safe human dose is, and any figure circulating online is extrapolated, not established.

What the literature actually contains:

• Animal studies most commonly used doses around 10 mcg/kg of body weight in rodents, with some studies ranging from roughly 1 to 100 mcg/kg, given by injection or orally depending on the model;
• Naive scaling of rodent doses to humans is unreliable — interspecies conversion involves body-surface-area math and unverified assumptions about absorption and metabolism;
• Gray-market products are typically sold as 5 mg vials intended to be reconstituted and drawn in microgram amounts, and online discussion commonly references figures in the hundreds of micrograms per day — these figures come from anecdote, not evidence, and are not validated by any human trial.

Nothing above is a recommendation. It is a description of what published animal studies used and an honest statement that human dosing has never been established.

BPC-157's reported elimination half-life is short — on the order of about 4 hours. Half-life is the time it takes for the amount of a compound in the body to fall by half; after roughly five half-lives (about a day, in this case), a single dose is essentially gone.

A short half-life has two practical implications for anyone tracking this compound in a research context. First, levels swing quickly: whatever is present after an injection declines within hours rather than days. Second, in the animal literature, dosing was typically daily or more frequent precisely because the compound clears fast — single weekly doses would leave long stretches with nothing measurable in circulation.

A worked example of the arithmetic: with a 4-hour half-life, whatever amount is present at noon has fallen to half by 4 p.m., a quarter by 8 p.m., and roughly 6% by midnight. Compare that with a compound like semaglutide, where the same decay steps take a month. The two ends of the half-life spectrum produce completely different tracking problems — one is about timing precision, the other about accumulation.

For record-keeping, this makes consistent timing and an accurate log more important than with long-acting compounds: a few hours' drift changes the concentration picture meaningfully.